YTS101 / BriSTAR Immunotech - LARVOL DELTA

BriSTAR Immunotech to Present at the BIO CEO & Investor Conference (PRNewswire) - "BriSTAR Immunotech...announced today that its Chief Executive Officer, James Pan, Ph.D., will be presenting at the 25th BIO CEO & Investor Conference....Dr. Pan's presentation will focus on how BriSTAR's STAR-T platform is used to formulate novel cell therapy candidates that better address the challenges in treating solid tumors....Dr. Pan will also discuss the latest developments for the Company's novel T cell immunotherapy candidates, including lead candidates CD19/CD20 STAR-T and LILRB4 STAR-T. CD19/CD20 STAR-T is currently in clinical trials targeting relapsed/refractory B-cell non-Hodgkin lymphoma and LILRB4 STAR-T is indicated for acute myeloid leukemia (AML)."

Clinical data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Non-Hodgkin’s Lymphoma • Oncology

CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Hebei Yanda Ludaopei Hospital | Suspended ➔ Completed | Trial completion date: Dec 2022 ➔ Feb 2022 | Trial primary completion date: Oct 2022 ➔ Oct 2021

Trial completion • Trial completion date • Trial primary completion date • Hematological Malignancies • Leukemia • Oncology • CD19 • CD20

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients (clinicaltrials.gov) - P1 | N=12 | Completed | Sponsor: Hebei Yanda Ludaopei Hospital | Suspended ➔ Completed | Trial completion date: Dec 2022 ➔ Sep 2021 | Trial primary completion date: Oct 2022 ➔ May 2021

Trial completion • Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD20

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients (clinicaltrials.gov) - P1 | N=12 | Suspended | Sponsor: Hebei Yanda Ludaopei Hospital | Trial completion date: Nov 2021 ➔ Dec 2022 | Recruiting ➔ Suspended | Trial primary completion date: Aug 2021 ➔ Oct 2022

Trial completion date • Trial primary completion date • Trial suspension • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD20

CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. (clinicaltrials.gov) - P1 | N=12 | Suspended | Sponsor: Beijing Tsinghua Chang Gung Hospital | Not yet recruiting ➔ Suspended

CAR T-Cell Therapy • Trial suspension • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD20

CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients (clinicaltrials.gov) - P1 | N=12 | Suspended | Sponsor: Hebei Yanda Ludaopei Hospital | Trial completion date: Nov 2021 ➔ Dec 2022 | Recruiting ➔ Suspended | Trial primary completion date: Aug 2021 ➔ Oct 2022

Trial completion date • Trial primary completion date • Trial suspension • Hematological Malignancies • Leukemia • Oncology • CD19 • CD20

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: Hebei Yanda Ludaopei Hospital; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD20

CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients (clinicaltrials.gov) - P1; N=12; Not yet recruiting; Sponsor: Hebei Yanda Ludaopei Hospital

Clinical • New P1 trial • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD20

CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. (clinicaltrials.gov) - P1; N=12; Not yet recruiting; Sponsor: Beijing Tsinghua Chang Gung Hospital

Clinical • New P1 trial • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • CD20

CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: Hebei Yanda Ludaopei Hospital; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hematological Malignancies • Leukemia • Oncology • CD19 • CD20